Ozempic vs. Wegovy: What's Actually Different?

Ozempic and Wegovy are the same drug. Both contain semaglutide — the same active molecule, manufactured by the same company (Novo Nordisk), injected the same way (once weekly, subcutaneously). If you've wondered why two different products seem to do the same thing, you're asking exactly the right question.

The differences are real, but they live in FDA-approved indications, maximum doses, insurance coverage pathways, and price. Understanding those distinctions is practically important — it can mean the difference between a medication costing $25/month or $1,200/month.

The Shared Foundation: Semaglutide

Semaglutide is a GLP-1 receptor agonist. It mimics the action of glucagon-like peptide-1, a hormone naturally released after eating that:

• Stimulates insulin secretion (glucose-dependent)
• Suppresses glucagon (reducing liver glucose output)
• Slows gastric emptying
• Acts on the hypothalamus and brainstem to reduce appetite and food intake

Originally developed for type 2 diabetes, Novo Nordisk's clinical programs demonstrated that higher doses produced meaningful weight loss in people without diabetes — leading to the separate product development, branding, and FDA approval of Wegovy.

Both drugs have the same molecular structure. Both are administered via subcutaneous injection. Both start at 0.25 mg/week and escalate.

FDA Approval: The Critical Difference

	Ozempic	Wegovy
FDA Approved For	Type 2 diabetes; cardiovascular risk reduction in T2D patients with established CVD	Chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related condition
Approval Year	2017	2021
Maintenance Dose	0.5 mg, 1.0 mg, or 2.0 mg weekly	2.4 mg weekly
Pen Doses Available	0.25 mg, 0.5 mg, 1 mg, 2 mg	0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg

The FDA approval for Wegovy in June 2021 was based on the STEP (Semaglutide Treatment Effect in People with obesity) clinical trial program, which used the 2.4 mg dose. The FDA approval for Ozempic for diabetes was based on the SUSTAIN trial program.

The highest approved dose of Ozempic is 2.0 mg — and that dose was added later, in 2022. Wegovy's maintenance dose of 2.4 mg is the highest approved semaglutide dose and is what drove the landmark weight loss results in STEP 1.

Weight Loss Results by Dose

Dose matters. A lot. Here's what the clinical data shows:

• Ozempic 1.0 mg (typical diabetes dose): ~4–6 kg weight loss in SUSTAIN trials
• Ozempic 2.0 mg: ~6–8 kg in SUSTAIN 7
• Wegovy 2.4 mg: ~15.3 kg (33.7 lbs) average weight loss over 68 weeks in STEP 1

This isn't a small difference. The dose matters enormously, and Wegovy's 2.4 mg approval was specifically designed to maximize weight loss outcomes. Using Ozempic at its diabetes-indicated doses for weight management produces meaningfully less weight loss on average.

Off-Label Use of Ozempic for Weight Loss

Because Ozempic is the same molecule as Wegovy, some providers prescribe it off-label for weight management in patients without diabetes. This is legal and relatively common — particularly when:

• Wegovy is out of stock (which has been a periodic issue since its 2021 launch)
• The patient's insurance covers Ozempic but not Wegovy
• The prescriber has a clinical reason to use a lower maintenance dose

However, off-label Ozempic for weight loss creates several issues:

1. Insurance won't cover it as a weight loss drug. Most commercial insurers specifically exclude off-label prescribing. You may pay out-of-pocket.
2. The maximum dose pen for Ozempic (2 mg) still doesn't reach Wegovy's 2.4 mg maintenance dose.
3. Novo Nordisk's savings cards are specific to indication. The Ozempic savings card is for diabetes; the Wegovy savings card is for obesity.

Insurance Coverage

This is where the practical rubber meets the road.

Ozempic (diabetes): - Widely covered by commercial insurance for T2D patients — it has been on formulary at major payers for years - Medicare Part D covers Ozempic for diabetes - Novo Nordisk offers a savings card reducing cost to as low as $25/month for eligible commercially insured patients

Wegovy (obesity): - Coverage has historically been inconsistent. The Treat and Reduce Obesity Act was intended to expand Medicare coverage to obesity drugs, but as of 2026 coverage remains variable. - Some commercial employers and large insurers cover Wegovy; others exclude obesity medications by category - Novo Nordisk's Wegovy savings program may reduce out-of-pocket cost to $0/month for eligible commercially insured patients who qualify - Without insurance: List price approximately $1,349/month (see our cost estimator for current pricing and savings options)

The American Obesity Association's ObesityActionCoalition maintains updated insurance coverage guidance and appeals resources.

Side Effect Profiles: Essentially the Same

Because it's the same molecule, the side effect profiles of Ozempic and Wegovy are effectively identical — nausea, vomiting, diarrhea, constipation, burping — just potentially more pronounced at Wegovy's higher 2.4 mg dose. The titration schedule (0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg over 16–20 weeks) is designed specifically to minimize side effects at each escalation.

Both carry the same FDA boxed warning regarding thyroid C-cell tumors (observed in rodent studies; clinical relevance in humans remains under investigation) and the same contraindication for patients with personal or family history of medullary thyroid carcinoma or MEN 2.

The Cardiovascular Angle

In 2024, the SELECT trial reported that semaglutide 2.4 mg (the Wegovy dose) reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% in adults with established cardiovascular disease, overweight or obesity, but without diabetes. This was a landmark finding — the first cardiovascular outcome trial for a GLP-1 medication in a predominantly non-diabetic population.

As a result, the FDA approved a new indication for Wegovy in March 2024: reducing cardiovascular risk in adults with obesity or overweight with established CVD. This may shift insurance coverage dynamics significantly, as cardiovascular indications have broader payer acceptance than obesity alone.

Ozempic, used at diabetes doses (0.5–2 mg), also demonstrated cardiovascular benefit in the SUSTAIN-6 trial, but those results were in type 2 diabetes patients.

Practical Decision Guide

Choose Wegovy if: - Your primary goal is weight management - You have BMI ≥30, or ≥27 with a weight-related condition (hypertension, sleep apnea, etc.) - Your insurance covers Wegovy - You want access to the full 2.4 mg dose and the maximum supported weight loss

Ozempic may be the right choice if: - You have type 2 diabetes (it's the approved indication) - Your insurance covers Ozempic but not Wegovy - Your provider determines a lower maintenance dose is appropriate - Supply issues affect Wegovy availability in your area

Discuss with your prescriber either way. The choice isn't purely clinical — it involves insurance, cost, access, and your specific metabolic situation.

Independent Analysis: The Ozempic / Wegovy Distinction Matters More for Coverage Than for Pharmacology

Three observations from the STEP and SUSTAIN trial data, the SELECT cardiovascular trial, and the FDA labeling history that clarify what this two-brand structure means clinically:

1. The weight loss difference is primarily a dose difference, not a brand difference

Comparing Ozempic to Wegovy weight loss numbers without controlling for dose and population produces misleading conclusions. Ozempic 0.5 mg produced approximately 3.5 kg weight loss in SUSTAIN-1 (a T2DM population). Wegovy 2.4 mg produced approximately 15.3 kg in STEP 1 (a non-diabetic obesity population). These numbers are not comparable — they involve different doses in different populations. The relevant comparison within a single population and dose range: STEP 2 (obese patients with T2DM on semaglutide 2.4 mg) produced 9.6% weight loss, while SUSTAIN-3 at semaglutide 1.0 mg in T2DM produced approximately 4.7%. The dose effect is real and large; the brand effect is not. A patient who obtains an Ozempic 1.0 mg prescription for weight loss is getting meaningfully less semaglutide than a patient on Wegovy 2.4 mg — not the same drug at a different name, but the same drug at a lower dose.

2. SELECT changed Wegovy's position relative to Ozempic in a clinically important way

The SELECT trial enrolled 17,604 adults with established cardiovascular disease who had overweight or obesity but not diabetes. Semaglutide 2.4 mg (Wegovy) reduced major adverse cardiovascular events (MACE) by 20% vs. placebo — a result that led the FDA to approve a new cardiovascular risk reduction indication for Wegovy in March 2024. Before SELECT, Ozempic had the cardiovascular risk reduction label (based on SUSTAIN-6 in T2DM patients) and Wegovy did not. After SELECT, Wegovy holds the cardiovascular indication for the non-diabetic obese cardiovascular population — a population Ozempic cannot be labeled for, because Ozempic's cardiovascular data comes from a T2DM population. This has created a Medicare Part D coverage pathway for Wegovy that does not exist for Ozempic in the same population. For non-diabetic patients with established CVD, Wegovy is now the pharmacologically and commercially preferred semaglutide product — a meaningful shift from 2022 positioning.

3. Off-label Ozempic prescribing for weight loss creates a dose ceiling problem

When Wegovy was in shortage in 2022–2023, many prescribers wrote Ozempic off-label for weight management in non-diabetic patients. Because Ozempic's maximum labeled dose is 2.0 mg (vs. 2.4 mg for Wegovy), and because the dose-response relationship for weight loss is meaningful across the 1.0–2.4 mg range, patients on off-label Ozempic could not reach the dose that produces Wegovy's trial outcomes. A patient expecting Wegovy-level results from Ozempic 1.0 mg is comparing different points on the dose-response curve, not equivalent treatments. As Wegovy supply improved through 2024 and 2025, most prescribers transitioned these patients back to Wegovy — but the dose ceiling confusion persists in patient communities where Ozempic and Wegovy are frequently treated as interchangeable at any dose.

What this means for patients choosing between the two brands

For patients with type 2 diabetes seeking weight loss: ask whether your insurance covers Wegovy under the SELECT CVD indication if you have established cardiovascular disease; if you have T2DM without CVD, Ozempic is likely covered while Wegovy may not be. For patients without diabetes seeking weight loss: Wegovy is the on-label choice, and the 2.4 mg dose is clinically important — lower doses on Ozempic are not equivalent. See our cost guide for savings programs for both brands and our titration guide for the semaglutide escalation schedule.

Frequently Asked Questions

Is Ozempic the same as Wegovy?

Both contain semaglutide, but they are not equivalent at maximum doses. Ozempic's maximum labeled dose for T2DM is 2.0 mg/week; Wegovy's maximum for weight management is 2.4 mg/week. At the same dose, the pharmacokinetics are identical. At their respective maximums, Wegovy provides more semaglutide, which corresponds to meaningfully greater average weight loss.

Can I take Ozempic for weight loss if I do not have diabetes?

Ozempic is not FDA-approved for weight loss in people without diabetes — Wegovy is. A prescriber can legally prescribe Ozempic off-label for weight management, and this was common during Wegovy shortages. However, the maximum Ozempic dose (2.0 mg) is below Wegovy's maximum (2.4 mg), so off-label Ozempic prescribing does not fully replicate Wegovy's labeled outcomes. Most prescribers now favor Wegovy directly for patients without T2DM.

Why does Ozempic get more coverage from insurance for weight loss than Wegovy?

It typically does not — it gets coverage specifically for its approved T2DM indication, not for weight loss. When a prescriber writes Ozempic for a T2DM patient, insurance covers it under the diabetes indication. When the goal is weight loss in a non-diabetic patient, neither Ozempic nor Wegovy is reliably covered by most commercial plans, though this is improving. Ozempic's apparent coverage advantage for weight loss in practice often reflects prescribers documenting a T2DM or prediabetes diagnosis as the primary indication.

What was the SELECT trial and why did it matter for Wegovy?

SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) enrolled over 17,600 adults with established cardiovascular disease and overweight/obesity but without diabetes. Semaglutide 2.4 mg reduced MACE by 20% vs. placebo over approximately 3 years. This led the FDA to approve a cardiovascular risk reduction indication for Wegovy in March 2024 — opening a Medicare Part D coverage pathway for patients with CVD who do not have diabetes.

What dose of semaglutide produces the most weight loss?

The dose-response relationship for weight loss is meaningful across the 0.5–2.4 mg range. STEP 1 showed 2.4 mg produced 14.9% average weight loss in non-diabetic adults; earlier STEP doses produce less. There is no published data for semaglutide above 2.4 mg for weight loss. Oral semaglutide 25 mg (OASIS-1 trial, different pharmacokinetics) produced 15.1% — roughly comparable to injectable 2.4 mg.

Can I switch from Ozempic to Wegovy and vice versa?

Yes, and this is pharmacologically straightforward. When switching, the prescriber should match the equivalent dose as closely as possible and continue on the same weekly injection schedule. No re-titration from a starting dose is typically needed when switching between brands at equivalent doses. Insurance approval may need to be re-obtained under the new brand name.

Does Wegovy 2.4 mg cause more side effects than Ozempic 2.0 mg?

Marginally, given the higher dose. The dose-response relationship for GI side effects mirrors the efficacy dose-response — higher doses produce modestly more nausea and GI events. In STEP 1, approximately 44% of patients on semaglutide 2.4 mg reported nausea at some point during the trial. SUSTAIN trials at lower doses showed lower nausea incidence. The difference between 2.0 mg and 2.4 mg is smaller than the difference between 0.5 mg and 2.4 mg.

Sources

1. Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)." NEJM, 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
2. FDA. "Wegovy (semaglutide) Prescribing Information." https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
3. FDA. "Ozempic (semaglutide) Prescribing Information." https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf
4. Lincoff AM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)." NEJM, 2023. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
5. FDA News Release. "FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight." March 2024. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or
6. Marso SP, et al. "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6)." NEJM, 2016. https://www.nejm.org/doi/full/10.1056/NEJMoa1607141